Effects of PAS therapy on the serum levels of Hcy and RBP4 in patients with diabetes mellitus complicated with cerebral infarction
10.3760/cma.j.cn431274-20181211-02313
- VernacularTitle:PAS疗法治疗2型糖尿病合并脑梗死患者的疗效及对血清Hcy和RBP4的影响
- Author:
Yue FANG
1
;
Meng ZHANG
;
Pengsi ZHANG
;
Dongmei PEI
Author Information
1. 中国医科大学附属盛京医院健康管理/全科医学科，沈阳 110004
- From:
Journal of Chinese Physician
2020;22(4):490-494
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of probucol + aspirin + atorvastatin (PAS) therapy on the serum levels of homocysteine (Hcy) and retinol binding protein 4 (RBP4) in patients with diabetes mellitus complicated with cerebral infarction.Methods:126 cases of cerebral infarction patients complicated with diabetes mellitus in our hospital were recruited during January 2014 to May 2017, and then all of them were randomly divided into control group and observation group, 63 cases in each group. The control group was treated with atorvastatin combined with aspirin on the basis of routine treatment (AS therapy), and the observation group received the probucol on that basis of control group (PAS therapy). The clinical efficacy, neurological function, complications, changes of serum inflammatory factors, Hcy and RBP4 were evaluated in both groups before and after treatment.Results:After treatment, the National Institute of Health Stroke Scale (NIHSS) score of both groups were decreased and the NIHSS score of the observation group was lower than that in the control group ( P<0.05). After treatment, the effective rate of clinical treatment in observation group and control group were respectively 87.3%, 68.3%, the effective rate of observation group was significantly higher than control group ( P<0.05). After treatment, the serum levels of tumor necrosis factors-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP), Hcy and RBP4 in both groups were decreased significantly ( P<0.05); the serum levels of TNF-α, hs-CRP, Hcy and RBP4 in observation group were significantly lower than those in control group ( P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups ( P>0.05). Conclusions:PAS therapy is safe and effective in the treatment of type 2 diabetes mellitus complicated with cerebral infarction, which can effectively reduce serum levels of Hcy and RBP4, relieve inflammatory injury and improve neurological function.
